Preclinical validation of Aurora kinases-targeting drugs in osteosarcomaElisa Tavanti(Istituto Ortopedico Rizzoli), Massimo Serra(Istituto Ortopedico Rizzoli)British Journal of CancerOctober 15, 201310.1038/bjc.2013.643Cited by 38SaveCiteExport RISWatch citationsRelated PapersTargeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells|PLoS ONE|2016|27